# A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

> **NCT00002184** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 120 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Nelfinavir mesylate
- **DRUG:** Levocarnitine
- **DRUG:** Adefovir dipivoxil
- **DRUG:** Saquinavir
- **DRUG:** Lamivudine
- **DRUG:** Stavudine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00002184
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 120 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002184, "A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*